Phase II study results showed that Avid Radiopharmaceuticals' 18F-AV-45 PET imaging agent helped measure high brain amyloid levels in cognitively normal subjects, as well as establish a link between the high amyloid levels and reduced memory function. The study also found that the mean 18F-AV-45 retention values in the brains of healthy subjects were significantly different from that of patients with Alzheimer's disease. "These results point to the need for further study of the earlier treatment of elevated amyloid levels in the brain with the goal of slowing the progression of this devastating disease," one of the results presenters said at an ongoing conference.

Full Story:

Related Summaries